Phage therapy, using bacteriophages to target and destroy bacteria, has evolved significantly from its early 20th-century inception to its modern resurgence as a promising alternative to antibiotics. This review explores the historical development of phage therapy, detailing its initial successes, subsequent decline with the rise of antibiotics, and recent revival in response to increasing antibiotic resistance. We examine the fundamental mechanisms of phage therapy, including the specificity of phages for bacterial targets and their ability to combat resistant strains. Current applications are discussed, highlighting the use of phage therapy in treating chronic infections, personalizing treatment strategies, and its role in veterinary and food safety contexts. Innovations in phage therapy, driven by advancements in genetic engineering and synthetic biology, are also reviewed, showcasing the development of engineered phages, phage libraries, and novel delivery systems. Despite its potential, phage therapy faces challenges such as regulatory hurdles, safety concerns, and issues related to bacterial resistance to phages. The review underscores the need for ongoing research and clinical trials to address these challenges and to integrate phage therapy into modern treatment paradigms. By offering a detailed overview of the evolution, current status, and future directions of phage therapy, this review aims to highlight its potential as a crucial component in the fight against antibiotic-resistant infections and to inform future research efforts.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11519598 | PMC |
http://dx.doi.org/10.7759/cureus.70414 | DOI Listing |
Curr Pharm Biotechnol
January 2025
Caliciviruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
The emergence of multiple antibiotic resistance in recurrent bacterial infections has led to exploring alternative therapeutic options, including using bacteria lysing viruses [bacteriophages] to control recalcitrant infections. Bacteriophages [Phage] and their end products such as enzymes, virus-like particles, and vectors are being used for varied applications such as basic and applied research for the field of phage therapeutics. Phage-based products and services such as viral vectors for gene therapy/vaccines, imaging agents, diagnostics as well as drug delivery agents form a wide range of useful innovative therapeutics that are under development.
View Article and Find Full Text PDFBMC Microbiol
January 2025
Zhongkai University of Agriculture and Engineering, Guangzhou, 510225, Guangdong, China.
Background: Salmonella enterica serovar Typhimurium is one of the most common serovars of Salmonella associated with clinical cases. It not only leads to diarrhea and mortality raised in livestock and poultry farming, but also poses a risk to food safety.
Results: In this study, a lytic bacteriophage named ZK22 was isolated and identified from sewage.
Drugs
January 2025
Bruce Rappaport Faculty of Medicine, Technion-Israel institute of technology, Haifa, Israel.
The human microbiome exerts profound influence over various biological processes within the body. Unlike many host determinants, it represents a readily accessible target for manipulation to promote health benefits. However, existing commercial microbiome-directed products often exhibit low efficacy.
View Article and Find Full Text PDFNPJ Antimicrob Resist
October 2024
Department of Microbiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Persistent bacterial lung infections in children lead to significant morbidity and mortality due to antibiotic resistance. In this paper, we describe how phage therapy has shown remarkable efficacy in preclinical and clinical studies, demonstrating significant therapeutic benefits through various administration routes. Ongoing trials are evaluating its safety and effectiveness against different pathogens.
View Article and Find Full Text PDFSci Rep
January 2025
Institute of Marine Biology, National Taiwan Ocean University, No. 2, Pei-Ning Road, Keelung, 20224, Taiwan, ROC.
Vibrio parahaemolyticus is pathogenic to both humans and marine animals. Antimicrobial-resistant (AMR) bacteria have been reported to cause mortalities in shrimp, with phage therapy presenting an alternative and eco-friendly biocontrol strategy for controlling bacterial diseases. Therefore, this study aimed to isolate and characterize phages for their applicability in lysing Vibrio parahaemolyticus.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!